Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.

There are also eye drops that can help with dry eyes caused by wearing contact ... we highly recommend the Sensitive Eyes Contact Lens Solution by Bausch + Lomb for anyone with sensitive eyes ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ... can occur in the late stages of dry aged-related macular degeneration ...

Bausch & Lomb Corp.’s stock soared 10% early ... Growth was driven by higher sales of Lumify eye drops, Eye Vitamins and Dry Eye Portfolio in the consumer eye-care business and higher sales ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Bausch + Lomb's product portfolio, particularly its prescription Dry Eye Disease (DED) offerings, has been a focal point for investors and analysts. The company's newest DED drug, Miebo ...